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HIGHLIGHTS 
 The term autoinflammatory keratinization diseases has been proposed as an umbrella term 
for inflammatory keratinization disorders with autoinflammatory pathomechanisms. 
 Integral diseases entities include IL36RN-related pustulosis, CARD14-mediated pustular 
psoriasis, pityriasis rubra pilaris type V and keratosis lichenoides chronica. 
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 Improved understanding of disease pathophysiology may lead to innovative targeted 
therapies. 
 
 
ABSTRACT 
 
Classifying inflammatory skin diseases is challenging, especially for the expanding group of 
disorders triggered by genetic factors resulting in hyperactivated innate immunity that result in 
overlapping patterns of dermal and epidermal inflammation with hyperkeratosis. For such 
conditions, the umbrella term “autoinflammatory keratinization diseases” (AIKD) has been 
proposed. AIKD encompasses diseases with mixed pathomechanisms of autoinflammation and 
autoimmunity, and includes IL-36 receptor antagonist (IL-36Ra)-related pustulosis, 
CARD14-mediated pustular psoriasis, pityriasis rubra pilaris (PRP) type V, and familial keratosis 
lichenoides chronica (KLC). Mechanistically, the entities include generalized pustular psoriasis 
(GPP) without psoriasis vulgaris, impetigo herpetiformis and acrodermatitis continua, which are 
IL-36Ra-related pustuloses caused by loss-of-function mutations in IL36RN; GPP with psoriasis 
vulgaris and palmoplantar pustular psoriasis which are CARD14-mediated pustular psoriasiform 
dermatoses with gain-of-function variants of CARD14; PRP type V which is caused by 
gain-of-function mutations in CARD14; and, familial KLC in which mutations in NLRP1, an 
inflammasome sensor protein predominantly expressed in skin, have been identified. It is likely 
that further inflammatory keratinization disorders will also fall within the concept of AIKD, as 
elucidation of novel pathogenic mechanisms of inflammatory keratinization diseases emerge. A 
better understanding of the pathophysiology of AIKD is likely to lead to innovative, targeted 
therapies that benefit patients. 
 
Abbreviations used: 
AIKD: autoinflammatory keratinization diseases 
CAPS: cryopyrin-associated periodic syndrome 
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CARD14: caspase recruitment domain family member 14 
FMF: familial Mediterranean fever 
GPP: generalized pustular psoriasis 
IL-36Ra: IL-36 receptor antagonist 
KLC: keratosis lichenoides chronica 
NLRP1: NLR family Pyrin domain-containing protein 1 
PAPA syndrome: syndrome of pyogenic arthritis with pyoderma gangrenosum and acne 
PRP: pityriasis rubra pilaris 
PV: psoriasis vulgaris 
TLR4: toll-like receptor 4 
TRAPS: TNF receptor-associated periodic fever syndrome 
 
Key words: autoinflammation, CARD14, IL-36 receptor antagonist, keratinization, 
keratosis lichenoides chronica, NLRP1, pityriasis rubra pilaris, psoriasis, psoriatic 
arthritis, pustular psoriasis 
 
1. Introduction 
 
Among the myriad diseases affecting the skin are a subset of disorders whose main pathobiology is 
inflammation, predominantly in the epidermis and the superficial dermis, that leads to 
hyperkeratosis, manifesting clinically as thickened scaly skin. These are designated as 
“inflammatory keratinization disorders”. The category includes many conditions that are poorly 
defined, although some, including psoriasis and lichen planus, are better categorized. 
 
Nevertheless, the pathogenic mechanisms of most inflammatory keratinization disorders remain 
unresolved. However, new pathogenic mechanisms relating to autoinflammation have been 
demonstrated in some inflammatory keratinization disorders, providing unexpected mechanistic 
insights and new ideas for targeted therapies. In 2017, we proposed a new umbrella term, 
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“autoinflammatory keratinization diseases” (AIKD), to encompass inflammatory keratinization 
disorders with autoinflammatory pathogenic mechanisms [1]. We herein summarize the concept of 
AIKD, review the diseases included in this disease subgrouping, and discuss the clinical value of 
grouping conditions as AIKD. 
 
2. What are AIKD? 
 
Our initial concept paper on AIKD defined the disease entities as having four inclusion criteria [1]: 
(1) the primary and main inflammation sites are the epidermis and the upper dermis; (2) the 
inflammation leads to hyperkeratosis, which is the main and characteristic phenotype of AIKD; (3) 
AIKD have primary genetic causative factors associated with the hyperactivation of innate 
immunity (autoinflammation), mainly in the epidermis and the upper dermis; (4) the spectrum of 
AIKD encompasses diseases with mixed pathomechanisms of autoinflammation and 
autoimmunity. Of note, in AIKD, genetic abnormalities leading to hyperactivation of the innate 
immune system predominantly are implicated in disease pathogenesis. In contrast, in 
inflammatory keratinization diseases without autoinflammatory pathogeneses (inflammatory 
keratinization diseases, non-autoinflammatory), no apparent genetic background susceptibility has 
been identified in most cases and the innate immune system involvement is not as significant. 
Points of differentiation between AIKD and inflammatory keratinization diseases, 
non-autoinflammatory are summarized in Table 1. To date, disorders included in AIKD comprise: 
IL-36 receptor antagonist (IL-36Ra)-related pustulosis, caspase recruitment domain family 
member 14 (CARD14)-mediated pustular psoriasis, pityriasis rubra pilaris (PRP) type V and 
keratosis lichenoides chronica (KLC) (Table 2) [1, 2]. As the causes and predisposing factors for 
inflammatory keratinization diseases come to be clarified, further disorders are also likely to be 
included in the AIKD category. For example, lichen planus, which may be triggered by factors 
such as medications, trauma or viruses, is currently regarded as non-autoinflammatory, yet new 
data on inflammasome pathology in other lichenoid diseases may lead to future reassignment of 
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lichen planus to within the AIKD grouping. (See the discussion below on NLR family Pyrin 
domain-containing protein 1, NLRP1). 
 
3. IL-36RA-related pustulosis 
 
In 2011, Marrakchi et al. [3] reported that IL36RN mutations leading to IL-36Ra deficiency were 
present in nine Tunisian families with recessively inherited familial generalized pustular psoriasis 
(GPP). IL36RN mutations were also reported as a genetic cause in three sporadic European GPP 
patients [4] and a Japanese GPP patient [5] (Fig. 1A, B). Subsequently, it was established that most 
sporadic GPP patients without preceding or concomitant psoriasis vulgaris (PV) skin lesions have 
IL36RN mutations as genetic predisposing or causative factors for the disease [6, 7]. Patients with 
certain other psoriasis-related pustular diseases including acrodermatitis continua of Hallopeau 
[8], severe acute generalized exanthematous pustulosis [9] and impetigo herpetiformis [10], have 
been reported to have IL36RN mutations as a genetic predisposing or causative factor.  
 
IL-36, IL-36 and IL-36 are absent in non-inflammatory skin, but they are generated by stimuli 
of inflammatory cytokines including TNF- and IL-17A [11]. IL-36, IL-36 and IL-36 are 
activated differentially by the neutrophil granule-derived proteases cathepsin G, elastase and 
proteinase-3, resulting in up to a 500-fold increase in their biological activities [12]. IL-36, 
IL-36 and IL-36 activate several pro-inflammatory signaling molecules including NFB [13]. 
The skin is the primary and main expression site of IL-36Ra. Mainly in the skin, IL-36Ra 
antagonizes the interleukin-1 family members IL-36 ,  and  [14, 15]. In this context, IL-36Ra 
deficiency caused by loss-of-function mutations in IL36RN is considered to induce and accelerate 
IL-36-driven inflammation in the skin [15]. Recently, Il36rn-/- mice treated with a toll-like receptor 
4 (TLR4) agonist were reported to show autoinflammatory symptoms in the skin, joints and liver; 
such mice have been established as a model of IL36Ra-deficient GPP [16]. 
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4. CARD14-mediated pustular psoriasis 
 
Psoriasis, one of the most common inflammatory keratinization disorders, is a chronic 
multifactorial inflammatory disease involving the skin, nails and joints [17]. The most common 
plaque-type psoriasis is psoriasis vulgaris (PV). Various inflammatory keratinization disorders 
such as psoriatic arthritis, GPP and palmoplantar pustular psoriasis (palmoplantar pustulosis) are 
known to be psoriasis-related diseases [18]. Recently, Arakawa et al. [19] demonstrated that 
melanocyte antigens can trigger autoimmunity in chronic PV, indicating that psoriasis has 
autoimmunity aspects and that acquired immunity may play a pathogenic role in psoriasis. In 
addition, it is widely accepted that psoriasis is a Th17-mediated disease rather than an 
inflammasome-driven one. This categorization is convincingly demonstrated by the much greater 
clinical efficacy of Th17-targeted biologics than IL-1-neutralizing therapies in PV. In light of this, 
inflammatory keratinization in psoriasis is not completely autonomous. However, psoriasis has 
innate and adaptive immune mechanisms implicated in its pathogenesis. Christophers et al. [20] 
suggested that, chronologically, in early or highly active lesions of psoriasis, inflammation begins 
as IL-1-TNF-mediated, neutrophil-dominant inflammation that induces Th17-dominant, early 
T-cell infiltration that develops into a Th1-dominant psoriasis plaque. This perspective remains 
controversial. For example, one recent publication identified IL-12 as a psoriasis-protective factor 
[21]. Furthermore, psoriasis is a group of highly heterogeneous diseases. Thus, autoimmunity and 
autoinflammation might be relevant to the inflammatory processes to different degrees in each 
clinical subset of psoriasis [22]. 
 
Recently, it has been documented that CARD14 gain-of-function variants/mutations may be risk 
factors for PV and psoriatic arthritis [23, 24].  Of note, the heterozygous CARD14 mutation, 
p.Gly117Ser, was identified in a large family with familial PV [23]. In addition, the rare de novo 
gain-of-function CARD14 variant p.Glu138Ala was reported in a sporadic patient with severe 
early-onset GPP [23]. Another rare CARD14 variant, p.Asp176His, was revealed to be a 
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significant risk factor for GPP with preceding or concomitant PV lesions, and was shown to 
underlie approximately 20% of GPP cases with PV in the Japanese population (compared to 3.0% 
in Japanese controls) [25]. In addition, concerning palmoplantar pustular psoriasis (palmoplantar 
pustulosis), CARD14 variants are thought to be a disease risk factor in European patients [26]. 
Autosomal dominant familial GPP caused by a CARD14 mutation was recently reported [2]. These 
data show that various phenotypes are seen in patients carrying CARD14 variants/mutations, with 
clear pathogenic implications for these findings in psoriasis and related diseases. 
 
CARD14 encodes the CARD family member CARD14. CARD14 is regarded as a scaffold protein 
regulating the signaling pathway of NF-B [23, 27, 28]. CARD14 is mainly expressed and 
localized in epidermal keratinocytes [23, 27]. In reports by Jordan et al., [23, 24] transfection 
experiments and studies using keratinocyte cell lines from patients with CARD14 mutations 
revealed that psoriasis-predisposing CARD14 mutations hyperactivate NF-B and accelerate the 
expression of certain psoriasis-associated genes in keratinocytes. Recently, CARD14 has been 
reported to form a signaling complex with BCL10 and the paracaspase MALT1, and 
psoriasis-associated CARD14 mutations were revealed to enhance this process in keratinocytes 
[29, 30]. These findings support the notion that, in inflammatory keratinization diseases associated 
with CARD14 mutations, the CARD14 mutations are involved in disease pathology in epidermal 
keratinocytes, although we cannot completely rule out the possibility that effects of CARD14 
mutations in immune cells may be partly responsible for disease pathogenesis. 
 
5. Pityriasis rubra pilaris (PRP) 
 
In addition, the concept of AIKD can also be applied to CARD14 mutation-driven inflammatory 
keratinization diseases, such as PRP type V. PRP is an inflammatory keratinization disease that 
shows general follicular plugging and perifollicular erythema with confluent configurations [31]. 
Pityriasis capitis and palmoplantar keratoderma are also seen in PRP [31]. In 1980, PRP was 
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classified into five subgroups, types I to V, based on clinical criteria (age of onset, distribution of 
lesions, disease course) [31]. The types are classical adult type (type I), atypical adult type (type 
II), classical juvenile type (type III), circumscribed juvenile type (type IV) and atypical juvenile 
type (type V). A further subtype, associated with HIV infection (PRP type VI), has been reported 
[32]. Patients with PRP are mostly sporadic cases [33]. However, familial cases have also been 
reported, mainly in PRP type V [33]. Indeed, this particular subtype of PRP differs somewhat from 
the other variants. Patients with type V PRP show skin symptoms from infancy or early childhood 
and usually have a chronic course without any long-standing resolution of the skin features. In 
2012, gain-of-function mutations in CARD14 were reported to underlie familial PRP cases with 
autosomal dominant inheritance [27]. We recently reported that all PRP type V patients in our 
series of PRP cases had CARD14 mutations (Fig. 1C-E) [34]. Furthermore, the symptoms and 
disease course of PRP patients who were reported to have CARD14 mutations were scrutinized, 
and notably, all the previously reported PRP patients harboring CARD14 mutations were clinically 
classified as PRP type V [34]. In contrast, among patients with the other types of PRP, no CARD14 
mutations were found, although a few CARD14 variants were observed in some patients [34]. 
Currently, nine heterozygous CARD14 mutations have been reported in type V PRP patients [27, 
34-37]. In light of the above, PRP type V, the atypical juvenile type, is thought to be a distinct 
variant of PRP with CARD14 mutations [34], and we propose that PRP type V is an AIKD. 
 
6. Familial keratosis lichenoides chronica (KLC) 
 
KLC is an infrequently seen inflammatory keratinization disorder. Kaposi first described KLC in 
1895, but the term KLC was formally proposed by Margolis in 1972 [38]. Patients with KLC show 
multiple small papules with confluent, linear and reticulate configurations on the trunk and 
extremities. KLC patients may also have seborrheic dermatitis-like eruptions on the face, 
palmoplantar keratoderma and hypertrophic nail deformities. These skin lesions are usually 
asymptomatic, but typically show chronic and frequently progressive courses. 
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Histopathologically, lichenoid interface dermatitis with numerous necrotic keratinocytes and 
parakeratosis are seen in lesional skin [38]. For a long time, the cause of KLC was unknown. Very 
recently, a gain-of-function mutation in NLRP1, the gene that encodes the inflammasome sensor 
protein NLRP1 was reported to underlie familial KLC in one family (Fig. 1F, G) [39]. Thereafter, 
one family and one sporadic patient with NLRP1 mutations were reported to have 
autoinflammation symptoms including follicular keratosis in the skin, as well as polyarthritis [40]. 
 
NLR proteins patrol the cytosol and initiate inflammasome assembly, pyroptotic cell death, and 
pro-inflammatory cytokine release upon ligand binding [41, 42]. Aberrant activation of 
inflammasomes is known to be pathogenic in a group of autoinflammatory syndromes with 
germline-activating mutations in inflammasome sensor proteins [43]. Another member of the 
NLR family of inflammasome sensor proteins, NLRP3 is well known as the causative molecule of 
the autoinflammatory syndrome cryopyrin-associated periodic syndrome (CAPS) [44]. 
  
NLRP1 was revealed to be one of the most highly produced inflammasome sensor proteins in the 
skin, and other components of inflammasomes, such as CASP1, ASC, IL-1 and IL-18, are also 
expressed in epidermal keratinocytes [39]. It was elucidated that wild-type NLRP1 retains its form 
as an inactive monomer by the combined action of the pyrin domain and a leucine-rich repeats 
domain. The KLC-causing mutation reported disrupts the leucine-rich repeats domain and part of 
the linker region, leading to constitutive NLRP1 self-oligomerization and inflammasome 
activation [39]. Excessive activation of inflammasomes and IL-1 secretion has been demonstrated 
in patient keratinocytes, and inflammasome-dependent IL-1 cytokines have been shown to cause 
the inflammatory familial KLC [39]. Thus, autoinflammation is thought to work in the 
pathogenesis of KLC, at least in that of familial KLC. Further studies are expected to yield 
information on similar pathogenic mechanisms associated with inflammasome signaling in 
sporadic KLC cases. 
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7. Therapies based on the pathomechanisms of AIKD  
 
Recently, various therapies based on the pathomechanisms of AIKD have achieved sufficient 
efficacy in several kinds of AIKD.  
 
Neutrophils are thought to be frequently involved in the inflammatory reaction induced in AIKD 
(Fig. 2). Thus, granulocyte and monocyte adsorption apheresis is expected to be effective for 
AIKD cases. Indeed, the treatment efficacy of granulocyte and monocyte adsorption apheresis was 
reported in a GPP case that resulted from an IL36RN mutation [45]. 
 
Concerning molecularly targeted therapies for GPP patients with IL-36Ra-related pustulosis, a 
successful therapy with the IL-1 receptor antagonist anakinra was reported in a patient with GPP 
caused by IL36RN mutations [46]. The IL-1 pathway is generally involved in the pathogenesis of 
AIKD (Fig. 2). In GPP with IL36RN mutations, the IL-1 pathway is downstream of the 
inflammatory reaction induced by IL-36 (Fig. 2). Thus, it is conceivable that the blockade of IL-1 
signaling is effective against GPP resulting from IL36RN mutations. TNF- is also generally 
involved in the inflammatory pathways in the pathogenesis of AIKD (Fig. 2), and infliximab, a 
monoclonal anti-human TNF- antibody, was reported to be effective in sibling cases of GPP with 
IL36RN mutations [47]. 
 
Furthermore, IL-12/IL-23 and IL-17 are thought to be involved in the inflammatory cascades that 
have been implicated in the pathogenesis of AIKD, including GPP with IL36RN mutations and 
PRP with CARD14 mutations (Fig. 2). In fact, the therapeutic efficacy of ustekinumab, a 
monoclonal anti-human IL-12/IL-23 p40 antibody, was suggested in GPP patients with and 
without IL36RN mutations [48]. Beneficial effects of ustekinumab were reported also in patients 
with PRP caused by CARD14 mutations [35, 37]. In addition, response to IL-17 inhibition was 
observed in an adolescent GPP patient with IL-36Ra deficiency [49]. 
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Although sufficient information has not been obtained concerning treatments for KLC resulting 
from NLRP1 mutations, anakinra seems to have some effectiveness in patients with 
NLRP1-associated autoinflammation with arthritis and dyskeratosis [40]. KLC-causative NLRP1 
mutations are known to overactivate inflammasomes and IL-1 secretion, resulting in the KLC 
phenotype [39] (Fig. 2). Thus, the IL-1 receptor antagonist anakinra is assumed to be effective as a 
treatment for KLC with NLRP1 mutations. 
 
In light of the above-mentioned findings, molecularly targeted therapies directing 
chemokines/cytokines and signal molecules involved in the inflammatory pathways of AIKD 
pathogenesis are promising, novel treatments for AIKD [16]. In this context, understanding the 
pathophysiology of severe inflammatory keratinization diseases with autoinflammatory 
pathogeneses, based on the recognition that they are AIKD, may give us significant clues to 
innovate highly effective, novel targeted therapies. 
 
8. Conclusions and future perspectives 
 
In 2017, the disease terminology AIKD was proposed for inflammatory keratinization disorders 
with autoinflammatory mechanisms as their main etiology (Fig. 2) [1]. The clinical entity of AIKD 
contains certain PRP type V, KLC, and subgroups of psoriasis-related diseases as described above 
(Table 2). 
 
The data summarized indicate that certain subsets of psoriasis and diseases related to it have 
genetic causes and predisposing factors associated with autoinflammatory mechanisms, such as 
CARD14 variants/mutations and IL36RN mutations. AIKD featured the hyperactivation of innate 
immunity (autoinflammation) resulting from genetic causative/predisposing factors as the 
predominant pathogenic mechanism. The concept of AIKD includes diseases with mixed 
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autoinflammation and autoimmune mechanisms, as opposed to purely autoinflammatory diseases 
such as familial Mediterranean fever (FMF) and CAPS (Table 3). In light of this, we think that rare 
subtypes of psoriasis and disorders related to it [50] (i.e., GPP, impetigo herpetiformis and 
acrodermatitis continua with IL36RN mutations) and GPP and palmoplantar pustular psoriasis 
(palmoplantar pustulosis) with CARD14 variants all fit within the category of AIKD. Furthermore, 
regarding the content of AIKD, although autoinflammatory mechanisms play a significant role in 
the inflammatory keratinization of the epidermis, we do not think that all the inflammatory 
processes need to manifest completely in epidermal keratinocytes in order for a disease to be 
categorized as an AIKD. 
 
Most conventional autoinflammatory diseases/syndromes are known to have skin symptoms. 
Their skin manifestations are various and include urticarial eruptions, erythema nodosum-like 
lesions and pustular acne. FMF shows erysipelas-like erythema, and CAPS often has urticarial 
eruptions. TNF receptor-associated periodic fever syndrome (TRAPS) shows migratory, urticarial 
erythema and purpuric macules. Blau syndrome/early onset sarcoidosis has granulomatous 
dermatitis, and the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne (PAPA 
syndrome) shows pustular acne and pyoderma gangrenosum. However, inflammatory eruptions 
with hyperkeratosis are uncommon in patients with conventional autoinflammatory 
diseases/syndromes. Therefore, while AIKD have autoinflammatory pathogenic mechanisms, 
AIKD are thought to cause distinctive inflammation that encompasses epidermal keratinocytes, 
leading to hyperkeratosis (Table 3). 
 
Recent advances in medical genetics have revealed genetic causes/predisposing factors for a 
number of inflammatory keratinization disorders of the skin whose etiology has long been 
unknown. Such new insights into the pathogeneses of these inflammatory keratinization disorders 
has established the novel disease concept of AIKD. We expect that more inflammatory 
keratinization disorders will be classified as AIKD in the future, as better elucidation of novel 
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pathogenic mechanisms of inflammatory keratinization diseases emerges. The identification of 
further genetic causes and disease susceptibility factors and the correct evaluation of their 
significance to disease pathogeneses promise to provide clues for further understanding the 
pathophysiology of AIKD and for developing innovative and more targeted therapies for the 
protean collection of autoinflammatory syndromes. 
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Figure legends 
 
Fig. 1. Clinical features of AIKD patients. 
Characteristic clinical features of GPP with IL36RN mutations (A, B), PRP type V with CARD14 
mutations (C-E) and familial KLC caused by NLRP1 mutations (F, G). Pustules and scaly 
hyperkeratosis are seen on erythrodermic skin on the chest and abdomen of an 18-month-old male 
(A) and on the lower leg of a 61-year-old male (B). Diffuse erythema with fine scaling is observed 
on the trunk (C) and on the legs (D) of a 20-year-old male. Severe hyperkeratosis with erythema is 
present on the palm of a 24-year-old female (E). A 10-month-old male infant shows seborrheic 
dermatitis-like eruptions on the face (F). A 10-year-old female patient has multiple small 
hyperkeratotic papules of reticulate configuration on the wrist (G). 
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Fig. 2. Inflammatory pathways involved in the pathogenesis of AIKD. 
Causative inflammatory pathways in the patients with IL-36Ra deficiency and gain-of-function 
mutations in CARD14 and NLRP1 are summarized. Up-regulated IL-36 signaling due to IL-36Ra 
deficiency (red starburst patterns) and gain-of-function mutant CARD14 (red arrows with blue 
starburst pattern) accelerate NFB activity, resulting in the secretion of the chemokines/cytokines 
IL-36, IL-8, CXCL1, CXCL2 and CCL20 by keratinocytes. The chemokines/cytokines induce the 
activation of neutrophils and dendritic cells in the superficial dermis. In addition, gain-of-function 
mutants of NLRP1 hyperactivate NLRP1 inflammasomes (blue starburst pattern) in keratinocytes, 
leading to the secretion of IL-1 and IL-18 and resulting in the activation of the paracrine signaling 
network in the epidermis and the superficial dermis. Black arrows: secretion or activation; green 
arrows: cell differentiation or chemotaxis; ⊥: inhibition. 
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Table 1 Summary of the differences between autoinflammatory keratinization diseases (AIKD) and 
inflammatory keratinization diseases, non-autoinflammatory 
Points of differentiation 
between the two concepts 
Autoinflammatory 
keratinization diseases 
(AIKD) 
Inflammatory keratinization 
diseases, non-autoinflammatory  
Pathogeneses   
Genetic causative factors CARD14, IL36RN, NLRP1 none or unknown 
Pathogenic mechanisms and 
pathways 
mainly autoinflammation 
(hyperactivation of innate 
immunity)  
(mixture of autoinflammation 
and autoimmunity)  
mainly autoimmunity 
(hyperactivation of acquired 
immunity) 
(Th17-mediated inflammation 
in psoriasis) 
Clinical features   
Family history common rare 
Disease course often persistent for life  transient, or persistent for life 
Extracutaneous symptoms occasional (arthritis, 
cholangitis) 
occasional (arthritis) 
Treatments Systemic treatments including 
immunosuppressants and 
biologics are often necessary. 
Topical treatments are often 
effective. Systemic treatments 
are needed in some cases. 
Representative diseases GPP, PRP type V, KLC psoriasis (the majority of cases), 
lichen planus 
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Table 2 Inflammatory keratinization diseases classified as AIKD to date 
Disease Genetic causative or predisposing factor 
(frequency) 
IL36Ra-relate
d pustulosis 
 
generalized pustular psoriasis 
(GPP) without PV 
IL36RN mutations (predominant) 
impetigo herpetiformis IL36RN mutations (predominant) 
acrodermatitis continua IL36RN mutations (occasional) 
CARD14-mediated pustular 
psoriasis 
 
GPP with PV CARD14 variants (occasional) 
palmoplantar pustular 
psoriasis (palmoplantar 
pustulosis) 
 
CARD14 variants (occasional) 
Pityriasis rubra pilaris (PRP)  
PRP type V CARD14 mutations (predominant) 
PRP other types CARD14 variants (infrequent) 
Keratosis 
lichenoides 
chronica 
(familial) 
NLRP1 mutation (unknown) 
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Table 3 Summary of the differences between autoinflammatory keratinization diseases (AIKD) and 
autoinflammatory diseases/syndromes 
Points of differentiation Autoinflammatory 
keratinization diseases (AIKD) 
Autoinflammatory 
diseases/syndromes 
Pathogeneses   
Main sites of inflammation skin (epidermis and upper 
dermis) 
all organs (but mainly joints, 
bones, eyes, muscles, mucous 
membranes, gastrointestinal 
tract, nervous system and skin 
(dermis)) 
Pathogenic mechanisms hyperactivation of innate 
immunity and related 
activation of acquired 
immunity (autoinflammation + 
autoimmunity) 
hyperactivation of innate 
immunity (autoinflammation) 
Main inflammation 
pathways involved 
CARD14/IL-36-driven 
NFB/MAPK activation, 
NLRP1-inflammasome-IL-1 
pathway 
inflammasome-driven IL-1 
pathway 
Phenotypes   
Skin symptoms hyperkeratosis with/without 
pustulosis (main phenotype) 
urticarial eruptions, 
erysipelas-like erythema, 
erythema nodosum-like 
lesions, pustular acne, 
pyoderma gangrenosum, 
granulomatous dermatitis 
Extracutaneous symptoms arthritis, cholangitis, fever 
(additional phenotypes) 
recurrent or persistent fever, 
arthritis, fatigue, 
conjunctivitis, neurosensory 
deafness, aseptic 
meningopathy, osteomyelitis 
Representative diseases GPP, PRP type V, KLC FMF, TRAPS, CAPS, PAPA 
syndrome 
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